Douglas S. Lehrer, MD

Associate Professor, Psychiatry
Summit Behavioral Health, 1101 Summit Rd, Cincinnati, OH 45237-2621


  • American Board of Psychiatry and Neurology: Psychiatry, 1993; Forensic Psychiatry, 1994

Academic Interests

  • Genetics of schizophrenia-spectrum disorders
  • Neuroimaging of schizophrenia-spectrum disorders
  • Forensic Psychiatry

Representative Publications

Peer-Reviewed Articles (selected)

Lehrer DS, Christian BT, Mantil J, Murray AC, Buchsbaum BR, Oakes T, Byne W, Kemether EM, Buchsbaum MS.  Thalamic and prefrontal FDG uptake in never-medicated patients with schizophrenia. Am J Psychiatry 2005;162:931–8.

Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer P, Buchsbaum MS, Mantil J.  Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task. NeuroImage 2006;31(1):139-52

Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes T, Mukherjee J.  D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006;85(1-3):232-244

Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric Comorbidities and Schizophrenia. Schizophr Bull 2009;35(2):383-402

Mossman D, Bowen MD, Vanness DJ, Bienenfeld D, Correll T, Kay J, Klykylo WM, Lehrer DS. Quantifying the Accuracy of Forensic Examiners in the Absence of a “Gold Standard.” Law & Human Behavior 2010 Oct;34(5):402-17. Epub 2009 Sep 22.

Lehrer DS, Christian BT, Kirbas C, Chiang M, Sidhu S, Short H, Wang B, Shi B, Chu K-W, Merrill B, Buchsbaum MS. 18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophrenia Research 2010;122(1-3):43-52

Pato MT, Sobell J, Medeiros H, Abbott C, Sklar B, Genomic Psychiatry Consortium, Buckley P, Bromet E, Escamilla M, Fanous A, Lehrer D, Macciardi F, Malaspina D, McCarroll S, Marder S, Morley C, Nicollini H, Perkins D, Purcell S, Rapaport M, Sklar P, Smoller J, Knowles JA, Pato CN. The Genomic Psychiatry Cohort: Partners in Discovery. Am J Med Genet Part B 2013;9999:1–7.

Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell J, Knowles JA, Bierut LJ, Pato MT, Genomic Psychiatry Cohort Consortium (GPCC)*. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71(3):248-254 [*Dr. Lehrer is a member and active participant in the GPCC.]

Lehrer DS, Lorenz J. Anosognosia in Schizophrenia: Hidden in Plain Sight. Innovations in Clinical Neuroscience. 2014;11(5-6):10-17.

McCullough PJ, Lehrer DS. Safety of oral vitamin D3 using daily doses of 5000 or 10,000 international units (IU) for 12 to 29 months in long-term hospitalized patients. [Submitted]

Book Chapters (selected)

Hoffman RE, McGlashan TH, Lehrer DS. Alterations of Speech, Thought, Perception, and Self-experience.  In:  Tasman A, Kay J, Lieberman J, First MB, Maj M (Eds.). Psychiatry, 3rd edition.  John Wiley & Sons, Ltd., London, 2008.

Lehrer DS, Dougherty DD, Rauch SL.  Brain Imaging in Psychiatry.  In: Tasman A, Kay J, Lieberman JA, First MB, Riba MB (Eds.). Psychiatry, 4th edition.  John Wiley & Sons, Ltd., London, in press.

Education History: 

M.D., University of Cincinnati College of Medicine, 1987

Residency, Psychiatry, University of Cincinnati Hospital, 1987-1991

Mental Health Executive Leadership Program, Weatherhead School of Management, Case Western Reserve University, Cleveland, 1996-97

Is this you? Log in to update your profile.